January 2026
M	T	W	T	F	S	S
	1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

High Lp(a): A Systemic Vascular Threat Beyond the Heart

Irma Bagdoniene/LinkedIn

Jan 5, 2026, 08:59

High Lp(a): A Systemic Vascular Threat Beyond the Heart

Irma Bagdoniene, Cardiologist Specializing in Prevention and Lipidology, Member of EAS, ESC and EAPC, shared on LinkedIn:

“Lp(a)’s threat goes far beyond the heart.

We often think of it mainly as a risk factor for heart attacks and strokes, but its impact actually involves the entire vascular system.

New data confirm that high Lp(a) is a causal risk factor for peripheral arterial disease, major adverse limb events, and abdominal aortic aneurysms. This risk stands independently of low-grade inflammation (hsCRP). Elevated Lp(a) by itself can drive these complications.

Key insights from the Copenhagen General Population Study and UK Biobank:

Individuals in the top 1% of Lp(a) levels face nearly a threefold increased risk of PAD and major adverse limb events.
Mendelian randomization studies support a causal relationship between genetically high Lp(a) and abdominal aortic aneurysms, with about a 40% increased risk per 50 mg/dL rise.
This elevated risk persists regardless of hsCRP levels. Low inflammation does not eliminate the vascular harm from Lp(a).
Four potent Lp(a)-lowering agents are currently in phase 3 trials (results expected between 2026 and 2029), holding promise to reshape prevention strategies across vascular diseases.

The clinical takeaway is straightforward.

We need to expand Lp(a) screening.”

Title: Lipoprotein(a) in cardiovascular disease with focus on peripheral arterial disease, major adverse limb events, abdominal aortic aneurysms and interaction with low-grade inflammation

Authors: Peter E. Thomas et al.

High Lp(a): A Systemic Vascular Threat Beyond the Heart